Log in or Sign up for Free to view tailored content for your specialty!
Therapeutics/Diagnostics News
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.
Prucalopride still effective in CIC despite older age, unhealthy BMI or renal impairment
Prucalopride was safe and effective in increasing the frequency of complete spontaneous bowel movements in patients with chronic idiopathic constipation, regardless of age, BMI or renal function, according to data.
Improved physician ADR from a baseline of less than 26% linked to lower CRC risk
Improvement in adenoma detection rate among physicians with a baseline rate of less than 26% was significantly associated with decreased patient risk for colorectal cancer, according to results of an observational study conducted in Poland.
Log in or Sign up for Free to view tailored content for your specialty!
Can uptick in noninvasive CRC screening tests compete with standard colonoscopy?
Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.
Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025
The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.
FDA approves Ionis’ Tryngolza as first treatment for familial chylomicronemia syndrome
The FDA approved Tryngolza for the treatment of adults with familial chylomicronemia syndrome when used in combination with an appropriate low-fat diet, according to an Ionis Pharmaceutical press release.
AGA updates living guideline on pharmacological management of moderate to severe UC
In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.
Concomitant use of common medications does not significantly affect UC induction therapy
Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed.
VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease
PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio.
Pharmacotherapy for alcohol use disorder ‘underutilized’ in at-risk populations
PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented at the ACG Annual Scientific Meeting.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read